Brümmer Lukas E, Ryckman Theresa S, Shrestha Sourya, Marx Florian M, Worodria William, Christopher Devasahayam J, Theron Grant, Cattamanchi Adithya, Denkinger Claudia M, Dowdy David W, Kendall Emily A
Division of Infectious Disease and Tropical Medicine, Center for Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany.
German Center for Infection Research (DZIF), Partner site Heidelberg, Germany.
medRxiv. 2025 May 11:2025.05.09.25327330. doi: 10.1101/2025.05.09.25327330.
Current active case-finding (ACF) efforts for tuberculosis (TB) are limited by the costs, operational barriers, and sensitivity of available tools to confirm a TB diagnosis. However, it is not well understood which of these limitations has the greatest epidemiological relevance and might therefore warrant prioritization in test development.
We developed a state-transition model of a one-time, community-based ACF intervention, with a fixed budget of one million United States dollars for screening and confirmatory testing. Assuming an adult population with four time the national prevalence of Uganda, we compared the impact of this intervention on TB diagnoses, mortality, and transmission when using a currently available confirmatory test (mirroring sputum-based Xpert Ultra) versus an improved confirmatory test. We considered the following test improvements: (1) increased sensitivity (from 69% to 80%), (2) non-sputum specimen type (increasing specimen availability from 93% to 100%), (3) immediate turn-around of test results (increasing delivery of positive results from 91% to 100%), (4) reduced costs (from $20 to $9 per confirmatory test). For those individuals not included in ACF efforts, TB outcomes under routine care were informed by recent natural history models.
In a simulated target population of 400,000 adults, 6,421 (1.6%; 95% uncertainty range [UR] 5,316-7,531) had TB disease, and 873 (612-1,182) were projected to die of TB in the absence of ACF. Assuming current tests, ACF efforts could reach 83,808 (59,388-118,601; 21% of the target population) people under the allotted budget, connecting 651 (429-983) individuals with TB to treatment and averting 76 (39-132) deaths. Of all hypothetical confirmatory test improvements modeled, higher diagnostic sensitivity most increased the number of people with TB who received treatment as a result of ACF (by 14% [4-26%]). However, considering mortality or transmission as a metric, the largest reductions resulted from tests that provided immediate turn-around of results (by 11% [5-18%]).
Making confirmatory tests for community-based TB screening more accessible and rapid may lead to greater population health benefits than further increasing sensitivity. Nonetheless, achieving large (>20%) increases in the health impact of ACF will require improvements to components of ACF other than the confirmatory diagnostic test.
目前用于结核病(TB)的主动病例发现(ACF)工作受到成本、操作障碍以及现有确诊工具对TB诊断的敏感性的限制。然而,目前尚不清楚这些限制因素中哪一个具有最大的流行病学相关性,因此在检测方法开发中可能需要优先考虑。
我们开发了一个基于社区的一次性ACF干预的状态转换模型,用于筛查和确诊检测的固定预算为100万美元。假设目标成年人群的患病率是乌干达全国患病率的4倍,我们比较了在使用现有确诊检测方法(类似基于痰液的Xpert Ultra)与改进的确诊检测方法时,这种干预措施对TB诊断、死亡率和传播的影响。我们考虑了以下检测方法的改进:(1)提高敏感性(从69%提高到80%),(2)非痰液标本类型(将标本可获得性从93%提高到100%),(3)检测结果即时反馈(将阳性结果的反馈率从91%提高到100%),(4)降低成本(从每次确诊检测20美元降至9美元)。对于那些未纳入ACF工作的个体,常规护理下的TB结局由近期的自然史模型提供信息。
在一个模拟的40万成年目标人群中,6421人(1.6%;95%不确定范围[UR]为5316 - 7531)患有TB疾病,在没有ACF的情况下,预计有873人(612 - 1182)将死于TB。假设使用当前检测方法,在分配的预算下,ACF工作可以覆盖83808人(59388 - 118601;占目标人群的21%),使651名(429 - 983)TB患者得到治疗,并避免76例(39 - 132)死亡。在所有模拟的假设确诊检测方法改进中,更高的诊断敏感性使因ACF而接受治疗的TB患者数量增加最多(增加了14%[4 - 26%])。然而,以死亡率或传播作为衡量标准,最大的降幅来自于能够即时反馈结果的检测方法(降低了11%[5 - 18%])。
相较于进一步提高敏感性,使基于社区的TB筛查的确诊检测方法更易获得且反馈更快,可能会给人群健康带来更大益处。尽管如此,要使ACF对健康的影响大幅(>20%)增加,将需要对ACF中确诊诊断检测方法以外的其他组成部分进行改进。